Spontaneous Dislocation and Adverse Events of a Prophylactic Pancreatic Stent

NCT ID: NCT07346365

Last Updated: 2026-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

358 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-01

Study Completion Date

2032-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter, prospective, controlled randomized study to investigate the optimal duration of protective pancreatic stents after endoscopic retrograde cholangiopancreatography (ERCP).

The primary endpoint is the complication rate that can be clinically attributed to the remaining pancreatic prosthesis or its removal in the study groups. Secondary endpoints are spontaneous removal of the pancreatic stent, length of hospital stay, rate of follow-up examinations per group, influencing factors, and a possible exploratory analysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After study consent, randomization takes place into the standard group (removal of the protective pancreatic stent after 12 hours at the earliest and 10 days at the latest by esophagogastroduodenoscopy/ERCP) or into the intervention group (removal of the protective pancreatic stent after 4 weeks at the earliest, but no later than 3 months).

Both the baseline data and randomization are planned on a secure online platform (http://myresearchmanager.com).

Before removing the pancreatic stent, non-invasive diagnostics may be performed in accordance with hospital standards, and endoscopy may be omitted if the pancreatic stent is found to be displaced.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stent Dislodgement ERCP Pancreas Stent Post-ERCP Pancreatitis Prophylactic Pancreatic Stent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard

Standard time of the removal

Group Type ACTIVE_COMPARATOR

standard group

Intervention Type DEVICE

Removal at intervals of 12 hours up to a maximum of 10 days after the index ERCP

Interventional - delayed removal

Stent removal after 1 - 3 months

Group Type EXPERIMENTAL

pancreatic stent removal

Intervention Type DEVICE

Removal of the pancreatic stent after 1 - 3 months after the placement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pancreatic stent removal

Removal of the pancreatic stent after 1 - 3 months after the placement

Intervention Type DEVICE

standard group

Removal at intervals of 12 hours up to a maximum of 10 days after the index ERCP

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* prophylactic pancreatic stent (5Fr 4cm length)
* informed consent

Exclusion Criteria

* necrotising post-ercp-pancreatitis
* pregnancy/breastfeeding
* Billroth II
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SRH Wald-Klinikum Gera GmbH

OTHER

Sponsor Role collaborator

Asklepios Kliniken Hamburg GmbH

OTHER

Sponsor Role collaborator

Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum

UNKNOWN

Sponsor Role collaborator

Helios Klinikum Krefeld

UNKNOWN

Sponsor Role collaborator

Sana Klinikum Offenbach

OTHER

Sponsor Role collaborator

St. Josef Hospital Bochum

OTHER

Sponsor Role collaborator

University Hospital, Aachen

OTHER

Sponsor Role collaborator

University Hospital, Essen

OTHER

Sponsor Role collaborator

University Hospital Freiburg

OTHER

Sponsor Role collaborator

Münster University Hospital, Germany

UNKNOWN

Sponsor Role collaborator

Medizinische Universitätsklinik Tübingen

UNKNOWN

Sponsor Role collaborator

University of Göttingen

OTHER

Sponsor Role collaborator

University Hospital, Basel, Switzerland

OTHER

Sponsor Role collaborator

Centrum Gastroenterologie Bethanien

UNKNOWN

Sponsor Role collaborator

University Hospital Munich (LMU)

UNKNOWN

Sponsor Role collaborator

Universitätsklinik Würzburg

UNKNOWN

Sponsor Role collaborator

Johann Wolfgang Goethe University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Georg Dultz

Senior Physician at Clinic of Gastroenterology, Johann Wolfgang Goethe University Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Johann Wolfgang Goethe-Universität Frankfurt am Main

Frankfurt, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Florian Michael, Dr. med.

Role: CONTACT

004915117191302

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Florian Michael, Dr. med.

Role: primary

004915117191302

References

Explore related publications, articles, or registry entries linked to this study.

Michael FA, Feldmann C, Erasmus HP, Kubesch A, Goerguelue E, Knabe M, Abedin N, Heilani M, Hessz D, Graf C, Walter D, Finkelmeier F, Mihm U, Lingwal N, Zeuzem S, Bojunga J, Friedrich-Rust M, Dultz G. A novel ultrasound-based algorithm for the detection of pancreatic stents placed for prophylaxis of post-ERCP pancreatitis: a prospective trial. Ultraschall Med. 2025 Apr;46(2):177-185. doi: 10.1055/a-2407-9651. Epub 2024 Sep 2.

Reference Type RESULT
PMID: 39222928 (View on PubMed)

Dultz G, Gerber L, Zeuzem S, Bojunga J, Friedrich-Rust M. Prolonged retention of prophylactic pancreatic stents is not associated with increased complications. Pancreatology. 2019 Jan;19(1):39-43. doi: 10.1016/j.pan.2018.11.011. Epub 2018 Nov 22.

Reference Type RESULT
PMID: 30502123 (View on PubMed)

Dumonceau JM, Kapral C, Aabakken L, Papanikolaou IS, Tringali A, Vanbiervliet G, Beyna T, Dinis-Ribeiro M, Hritz I, Mariani A, Paspatis G, Radaelli F, Lakhtakia S, Veitch AM, van Hooft JE. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2020 Feb;52(2):127-149. doi: 10.1055/a-1075-4080. Epub 2019 Dec 20.

Reference Type RESULT
PMID: 31863440 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FloMi2025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Organoids for Bile Leaks
NCT07214649 NOT_YET_RECRUITING PHASE2